Castlevax INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersNew York, NY
SAM.gov UEIFLZ6THBQ53N3
CAGE code9M4Y5
Incorporated inDE
CastleVax develops mucosal vaccines using a platform based on Newcastle Disease Virus (NDV) as a viral vector. The company is in clinical-stage development with a COVID-19 vaccine candidate currently in Phase 2 testing. The platform is designed to enable rapid development of vaccines for respiratory diseases delivered through mucosal routes rather than systemic delivery.
Summarized from the company’s own website
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Castlevax INC | New York | NY | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.